Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.

被引：50
|
作者：
Sullivan, Ryan J.
Hong, David S.
Tolcher, Anthony W.
Patnaik, Amita
Shapiro, Geoffrey
Chmielowski, Bartosz
Ribas, Antoni
Brail, Les H.
Roberts, Jennifer
Lee, Lucy
O'Connell, Brenda
Kutok, Jeffrey Lorne
Mahabhashyam, Suresh
Ullmann, Claudio Dansky
Postow, Michael A.
Wolchok, Jedd D.
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[6] Infin Pharmaceut Inc, Cambridge, MA USA
[7] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3013
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A first-in-human study of CRISPR/Cas9-engineered tumor infiltrating lymphocytes (TILs) product GT316 as monotherapy in advanced solid tumors.
    Guo, Jing
    Huang, Wei
    Zhao, Binghui
    Yu, Jing
    Cui, Jun
    Sun, Jingwei
    Ma, Liqing
    Liu, Yishan
    Shen, Derun
    Shen, Lin
    Wang, Pin
    Liu, Yarong
    Cheng, Zhongping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors
    Dumbrava, Ecaterina Elena
    Cecchini, Michael
    Zugazagoitia, Jon
    Lopez, Juanita Suzanne
    Jager, Dirk
    Oliva, Marc
    Ochsenreither, Sebastian
    Gambardella, Valentina
    Chung, Ki Y.
    Longo, Federico
    Razak, Albiruni Ryan Abdul
    Wermke, Martin
    Evans, T. R. Jeffry
    Cook, Natalie
    Chenard-Poirier, Maxime
    Pencheva, Radost
    Schaer, David
    Wagener, Thomas
    Wagner, Andrea
    Papadopoulos, Kyriakos P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors.
    Aftimos, Philippe G.
    Barthelemy, Philippe
    Rolfo, Christian D.
    Hanssens, Valerie
    De Jonge, Natalie
    Silence, Karen
    Dreier, Torsten
    de Haard, Hans
    Peeters, Marc
    Thibault, Alain
    Awada, Ahmad
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] First-in-human phase I study of the antiangiogenic vaccine (OTS11101) targeting VEGFR-1 in patients with solid tumors.
    Hayashi, H.
    Kurata, T.
    Fujisaka, Y.
    Satoh, T.
    Takeda, M.
    Miyazaki, M.
    Okabe, T.
    Kiyota, H.
    Tanaka, K.
    Tsunoda, T.
    Nakagawa, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] A first-in-human phase 1 study of the safety and pharmacokinetics of XB002 in patients with inoperable locally advanced or metastatic solid tumors.
    Johnson, Melissa
    Ulahannan, Susanna
    Vandross, Andrae
    Park, Haeseong
    Faoro, Leo
    Faggioni, Raffaella
    Li, Jing
    Chang, Yu-Lin
    Uttamsingh, Shailaja
    Tolcher, Anthony
    CANCER RESEARCH, 2022, 82 (12)
  • [26] Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
    Lin, C-C.
    Schneider, R.
    Gutierrez, M.
    Shen, L.
    Chung, K.
    Doroshow, D. B.
    Gao, B.
    Millward, M.
    Hsieh, C-Y.
    Xu, C.
    Cai, S. X.
    Tian, Y. E.
    Liu, L.
    Shen, C.
    Tan, Y.
    He, Y.
    Zhang, C.
    Li, L.
    Ma, M.
    Xu, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S503 - S504
  • [27] Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors.
    Powderly, John
    Shimizu, Toshio
    LoRusso, Patricia
    Razak, Albiruni
    Miller, Kathy
    Balar, Arjun
    Bruix, Jordi
    Michel, Loren
    Blaney, Martha
    Guan, Xiaowen
    Lacy, Susan
    Lally, Satwant
    Lambert, Stacie
    Leibman, Rachel
    Vosganian, Gregory
    Golan, Talia
    Tolcher, Anthony
    CANCER RESEARCH, 2021, 81 (13)
  • [28] A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors.
    Burris, Howard A., III
    Spira, Alexander I.
    Taylor, Matthew H.
    Yeku, Oladapo O.
    Liu, Joyce F.
    Munster, Pamela N.
    Hamilton, Erika P.
    Thomas, Jacob Stephen
    Gatlin, Frances
    Penson, Richard T.
    Abrams, Thomas Adam
    Dhawan, Mallika Sachdev
    Walling, Jacqueline M.
    Frye, John W.
    Romanko, Kevin
    Sung, Victoria
    Brachmann, Carrie
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.
    Falchook, Gerald Steven
    Patel, Manish R.
    Yap, Timothy A.
    McEachern, Kristen
    Kuplast-Barr, Kristy
    Utley, Luke
    Cleary, Lisa
    Manyak, Erika
    Bozon, Viviana
    Parasuraman, Sudha
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] FIRST-IN-HUMAN RESULTS WITH THE NOVEL TUMOR-TARGETING ANTIBODY ATRC-101: PHASE 1B STUDY IN PATIENTS WITH SOLID TUMORS
    Powderly, John
    Jones, Jeremy
    Bekaii-Saab, Tanios
    Xing, Yan
    Weroha, S. John
    Ulahannan, Susanna
    Doroshow, Deborah
    Valdes-Albini, Frances
    Millward, Carl
    Walter, Kimberly
    Wrong, Andrew
    Del Castillo, Paul
    Wang, Lixia
    Ngan Nguyen
    Whidden, Mark
    Benjamin, Jonathan
    Isakoff, Steven
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A548 - A548
12345